Navigation Links
Argos Therapeutics to Present Corporate Overview and Next Steps in Clinical Development of Arcelis™ Immunotherapy at Lazard Capital Markets 7th Annual Healthcare Conference
Date:11/11/2010

DURHAM, N.C., Nov. 11, 2010 /PRNewswire/ -- Argos Therapeutics today announced that Jeff Abbey, the company's president and chief executive officer, will present a corporate overview and the next steps in the clinical development of Argos' Arcelis™ immunotherapy at the Lazard Capital Markets 7th Annual Healthcare Conference in New York at 11 a.m. EST on Wednesday, Nov. 17, 2010.  The conference will take place at The St. Regis New York.

Argos is in the process of securing funding to begin a Phase 3 trial in renal cell carcinoma (RCC) with its Arcelis immunotherapy, AGS 003, in mid-2011.  The company recently presented favorable progression-free survival and safety results from an ongoing Phase 2 trial for AGS 003 in combination with sunitinib. Argos' Arcelis HIV program, AGS-004, is also currently being tested in a double-blind, placebo controlled, randomized Phase 2b study co-funded by the NIH to further demonstrate that it is a feasible treatment option of HIV-1 infected patients.

About the Arcelis™ Technology

Arcelis is Argos' proprietary technology for personalizing RNA-loaded dendritic cell immunotherapies for cancer, HIV and other infectious diseases. This platform is based on optimizing a patient's own (autologous) dendritic cells to trigger a tumor- or pathogen-specific immune response. To address the challenge of the unique genetic profile of each patient's disease and the genetic mutations of that disease, Argos loads the autologous dendritic cells with a sample of messenger RNA ("mRNA") isolated from the patient's disease. Through this process, dendritic cells can potentially prime immune responses to the entire antigenic repertoire, resulting in an immunotherapeutic that is customized to the patient's specific disease.

About Argos Therapeutics, Inc.Argos is an immunotherapy c
'/>"/>

SOURCE Argos Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Silence Therapeutics Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
2. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
3. NASDAQ Grants Cell Therapeutics 180-Day Extension to Regain Compliance With Minimum Bid Price Rule
4. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
5. Orexigen® Therapeutics Schedules November 3, 2010 Webcast Discussion of Financial Results for the Third Quarter Ended September 30, 2010
6. United Therapeutics Corporation Reports Third Quarter 2010 Financial Results
7. Cell Therapeutics, Inc. (CTI) to Report Third Quarter 2010 Financial Results on October 28
8. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
9. United Therapeutics Corporation to Announce Third Quarter 2010 Financial Results Before Market Open on Thursday, October 28, 2010
10. Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
11. Precision Therapeutics President and CEO Sean McDonald Recognized as Pittsburgh Technology Council Tech 50 CEO of the Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... The ability for organizations to attract top ... individuals to perform at the highest of levels, are ... to compete in this post–recession era. The pharmaceutical ... the sector increasingly focuses on the importance of employee-fit ... real results on the organization's development and the innovation ...
(Date:8/28/2014)... by a Florida State University research team has led ... temperature, emit white light, and convert photon energy directly ... a butterfly. , Biwu Ma, associate professor in the ... College of Engineering, created the molecule in a lab ... that his creation has many other unique capabilities. , ...
(Date:8/28/2014)... Supplementing their complete line of ... Eppendorf Safe Lock Centrifuge Tubes . This ... quality tubes at an affordable price. Eppendorf Safe ... chemical, medical, pharmaceutical, and life science research and ... able to afford Eppendorf products. , Eppendorf is ...
(Date:8/27/2014)... Livermore, California (PRWEB) August 27, 2014 ... (LLNL), through Lawrence Livermore National Security ... million to develop and deliver a state-of-the-art laser ... Beamlines facility (ELI Beamlines), under construction in the ... design performance, the laser system, called the " ...
Breaking Biology Technology:Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3Novel 'butterfly' molecule could build new sensors, photoenergy conversion devices 2Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 2Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 3LLNL Synchs up with ELI Beamlines on Timing System 2LLNL Synchs up with ELI Beamlines on Timing System 3
... , , , Danny Q. Hoang ... Cloning Systems, Inc. , , Stratagene introduces affinity ... for studying expression of the NR2A, NR2B and ... regions. These antibodies,have been used in Western blot ...
... all-purpose power supply , Douglas Drake Michelle Cayouette Lisa Filippone ,Bob LeSchofs ... , , ... Stratagene has developed the new SmartPower , ... electrophoretic application. The SmartPower 4000 power supply has been, ...
... ,,,, A streamlined and reliable method ... Braman Scott Basehore ,Stratagene , The ... purification kit allows,easy, quick, and reliable purification ... DNA recovered from phage lysate exceeds the ...
Cached Biology Technology:Antibodies for Studying NMDA Receptor Protein Expression and,Synapse-Specific Immunolabeling 2Antibodies for Studying NMDA Receptor Protein Expression and,Synapse-Specific Immunolabeling 3Antibodies for Studying NMDA Receptor Protein Expression and,Synapse-Specific Immunolabeling 4A Versatile Power Supply for All Electrophoresis Applications 2A Versatile Power Supply for All Electrophoresis Applications 3A Versatile Power Supply for All Electrophoresis Applications 4A Versatile Power Supply for All Electrophoresis Applications 5Purified Single-Stranded M13 DNA for Automated Sequencing 2Purified Single-Stranded M13 DNA for Automated Sequencing 3
(Date:8/28/2014)... A Mayo Clinic researcher and his collaborators have developed ... enhance the process of re-engineering cells for biomedical investigation. ... biology methods to aid stem cell engineering. Details of ... described in two back-to-back papers in the journal ... range of uses for all types of cell-based investigations ...
(Date:8/28/2014)... Athens, Ga. The support of peer groups ... effective breastfeeding programs, according to recent University of ... mothers in the Athens-Clarke County area determined that ... the outcomes of mothers of infants. , "Mothers ... be successful at breastfeeding," said study co-author Alex ...
(Date:8/28/2014)... A unique method for delivering compounds that ... HIV and AIDS may be possible, thanks ... Agricultural Sciences., A semi-soft vaginal suppository made ... loaded with the antiviral drug Tenofovir provides ... against the spread of sexually transmitted infections ...
Breaking Biology News(10 mins):New tool aids stem cell engineering for medical research 2Breastfeeding study shows need for effective peer counseling programs 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 3
... fish farming can be accomplished with minimal or no ... proper planning and safeguards are in place, according to ... Service. The study, led by scientists at National ... evaluated the environmental effects of finfish aquaculture, including interactions ...
... restaurant reduces the calories in a children,s meal by ... French fries? Would children compensate by choosing a more ... Dr. Brian Wansink and Dr. Andrew Hanks, analyzed transaction ... question. Prior to 2012, the Happy Meal was ...
... the potential to threaten people and nature, and that it ... greenhouse gases. One way to slow climate change is to ... photosynthesis, take up the greenhouse gas carbon dioxide, converting it ... the form of wood, roots, leaves) and oxygen. New ...
Cached Biology News:Healthier Happy Meals 2Big data project reveals where carbon-stocking projects in Africa provide the greatest benefits 2Big data project reveals where carbon-stocking projects in Africa provide the greatest benefits 3
Ras-related C3 botulinum toxin substrate 1...
Human sVCAM-1/CD106 ELI-PAIR Kit...
HP 1 alpha Immunogen: Synthetic peptide between amino acids 1-100 of the human HP 1 alpha protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
... Services include subcloning of gene in ... cells, isolation and plaque purification of ... virus stock for one clone, protein ... insect cell culture. Expected yield and ...
Biology Products: